Connection

Weijin Huang to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications Weijin Huang has written about Antibodies, Neutralizing.
Weijin Huang
Connection Strength
0.674
Antibodies, Neutralizing
  1. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021; 12:687869.
    View in: PubMed
    Score: 0.134
  2. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerg Microbes Infect. 2021 Dec; 10(1):1390-1403.
    View in: PubMed
    Score: 0.035
  3. Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. Cell Res. 2021 10; 31(10):1130-1133.
    View in: PubMed
    Score: 0.034
  4. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat Commun. 2021 08 17; 12(1):5000.
    View in: PubMed
    Score: 0.034
  5. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021 07 09; 12(1):4210.
    View in: PubMed
    Score: 0.034
  6. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021 07; 31(7):732-741.
    View in: PubMed
    Score: 0.033
  7. The first Chinese national standards for SARS-CoV-2 neutralizing antibody. Vaccine. 2021 06 23; 39(28):3724-3730.
    View in: PubMed
    Score: 0.033
  8. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020 Dec; 9(1):680-686.
    View in: PubMed
    Score: 0.032
  9. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020 11 13; 11(1):5752.
    View in: PubMed
    Score: 0.032
  10. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front Med. 2020 Dec; 14(6):746-751.
    View in: PubMed
    Score: 0.032
  11. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020 11; 15(11):3699-3715.
    View in: PubMed
    Score: 0.032
  12. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell. 2020 11 12; 183(4):1013-1023.e13.
    View in: PubMed
    Score: 0.032
  13. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020 09 18; 369(6510):1505-1509.
    View in: PubMed
    Score: 0.031
  14. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020 08; 584(7819):120-124.
    View in: PubMed
    Score: 0.031
  15. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. Vaccine. 2017 09 12; 35(38):5172-5178.
    View in: PubMed
    Score: 0.026
  16. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerg Microbes Infect. 2021 Dec; 10(1):1574-1588.
    View in: PubMed
    Score: 0.009
  17. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021 03 01; 12(1):1346.
    View in: PubMed
    Score: 0.008
  18. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021 04 29; 184(9):2362-2371.e9.
    View in: PubMed
    Score: 0.008
  19. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat Microbiol. 2021 01; 6(1):51-58.
    View in: PubMed
    Score: 0.008
  20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 01; 21(1):39-51.
    View in: PubMed
    Score: 0.008
  21. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020 10; 586(7830):572-577.
    View in: PubMed
    Score: 0.008
  22. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020 09 03; 182(5):1271-1283.e16.
    View in: PubMed
    Score: 0.008
  23. Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities. Emerg Microbes Infect. 2019; 8(1):272-281.
    View in: PubMed
    Score: 0.007
  24. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses. 2018 08 23; 10(9).
    View in: PubMed
    Score: 0.007
  25. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. Hum Vaccin Immunother. 2018 01 02; 14(1):199-208.
    View in: PubMed
    Score: 0.006
  26. Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization. J Infect Dis. 2017 10 17; 216(7):867-876.
    View in: PubMed
    Score: 0.006
  27. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep. 2017 03 30; 7:45552.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.